Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff as set forth below.

The Board of Directors has previously granted share options and performance shares in ALK-Abelló A/S, re. company releases nos. 7/2018 and 8/2018 of 20 March 2018. The right to performance shares and determination of the final number to be allocated may be achieved in March 2021, provided that ALK achieves the pre-agreed targets for vesting and that the employment relationship with the ALK Group has not been terminated by the Company on objective grounds or terminated.

The final calculations have now been completed, and final allocation of share options and delivery of performance shares have taken place as stated in the attached pdf.

Please note that for the special incentive plan – the equity-based one-time scheme – the overall pay-out of the plan on the vesting date for the performance shares and on the exercise date for the share options can never exceed a total value of 300% of the recipient’s 2018 annual base salary. This means that the amount stated under final allocation of shares is the maximum gain. The final number of share options is determined at the time of exercise.

ALK-Abelló A/S

For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014

This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.

About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,400 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment


Börskollens app – Högt betyg ⭐⭐⭐⭐⭐ och 250.000 nedladdningar

Ladda hem

Vårt nyhetsbrev – Utvalda börsnyheter och heta investeringscase varje vecka

Prenumerera

Nyheter om ALK-Abello

Läses av andra just nu

Innehåller annonslänkar

Så kommer du igång med trading

Den här månaden har vi valt att lyfta fram trading som utbildningstema, så att du som läsare ska få en möjlighet att fördjupa dig mer och spetsa dina kunskaper. Nedan finner du ett antal matiga guider och vi lyfter även fram vårt förstahandsval av mäklare och plattform: IG.

STÄNG X
Bästa valet för trading – Bra erbjudande & gratis utbildning
Världsledande global tradingmäklare med prisbelönt app
Gratis att öppna konto & demokonto (fiktiv handel)
KOM IGÅNG

74% av alla icke-professionella kunder förlorar pengar på CFD-handel hos de här leverantörerna.

Om aktien ALK-Abello

Senaste nytt